Vaughan / Osbourn / Jallal Protein Therapeutics

1. Auflage 2017
ISBN: 978-3-527-69914-8
Verlag: Wiley-VCH
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 718 Seiten, E-Book

Reihe: Methods and Principles in Medicinal Chemistry

Branchenführende Big-Pharma-Unternehmen und erstklassige Forscher präsentieren grundlegende Konzepte und Herausforderungen bei proteinbasierten Pharmazeutika. Beinhaltet auch eine Einführung in die aus Sicht der Arzneimittelentwicklung fünf wesentlichen Anwendungsbereiche.

Autoren/Hrsg.

Vaughan, Tristan

Osbourn, Jane

Jallal, Bahija

Weitere Mitwirkende

Mannhold, Raimund

Folkers, Gerd

Buschmann, Helmut

Inhaltsverzeichnis

PART 1 - Introduction to Protein therapeutics: past and present
Early recombinant protein therapeutics
Evolution of antibody therapeutics
PART 2 - Antibodies: the ultimate scaffold for protein therapeutics
Human antibody Structure and Function
Antibodies from other species
PART 3 - Discovery and engineering of protein therapeutics
Human antibody discovery platforms
Non-antibody scaffolds and antibody mimetics
Protein engineering: methods and applications
Bispecifics
Antibody-drug conjugates
PART 4 - Physiological and manufacturing considerations for biologics
Pharmacokinetics
Safety Considerations for Biologics
Immunogenicity
Expression Systems for manufacture
Stability, formulation and delivery
PART 5 - Clinical applications
Protein therapeutics in autoimmune and inflammatory diseases
Protein therapeutics in oncology
Protein therapeutics in respiratory diseases
Protein therapeutics in infectious diseases and other indications
Rescue therapies
Biosimilars
PART 6 - Future horizons
Future horizons and new target class opportunities

Über Autor(innen)

Tristan Vaughan is Vice President, Research and Development for antibody discovery and protein engineering at MedImmune. Based in Cambridge (UK), Dr. Vaughan leads the work of 110 scientists who are responsible for discovering and engineering around half of MedImmune's biologics portfolio, and who have delivered over 50 protein-based therapeutic candidates into the clinical phases of development. Dr. Vaughan joined MedImmune, previously Cambridge Antibody Technology, in 1993 and developed the platform technology which built the first human antibody libraries of 10 E10 members. He is also a key inventor of Humira and Benlysta. Dr. Vaughan has over 60 publications in peer-reviewed journals to his name.
 
Jane Osbourn is Vice President, Research and Development at MedImmune and Site Leader for MedImmune Cambridge (UK). An expert in antibody engineering, Dr. Osbourn joined MedImmune, formerly Cambridge Antibody Technology, in 1993, and is an originator of key peer-reviewed publications and patents. She made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. Dr. Osbourn has worked across a range of disease areas and currently leads a team of researchers developing biosuperior biologics medicines in oncology, cardiovascular disease and diabetes. In addition, she is Chair of the UK BioIndustry Association, a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise.

Bahija Jallal is Executive Vice President of AstraZeneca and head of MedImmune, its global biologics research and development arm, based in Gaithersburg (USA). Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company's translational medicine group. In 2013, Dr. Jallal earned the Grace Award from the Cancer Research Institute. She has authored over 70 peer-reviewed publications and has over 15 patents.